– SWEDEN, Lund – Active Biotech (NASDAQ: ACTI) today announced that its Election Committee proposed that Michael Shalmi and Uli Hacksell be appointed new members of the Board of Directors and that Michael Shalmi be appointed Chairman of the Board of Directors. Mats Arnhög and Magnhild Sandberg have declined re-election.
About Michael Shalmi.
Michael Shalmi, born in 1965 and Danish citizen graduated as a physician from the University of Copenhagen and obtained his MBA following studies at Scandinavian International Management Institute in Copenhagen. Previously, Michael Shalmi served as Managing Director and Head of Principal Investments of Novo Holdings A/S. He holds a position as director of the Supervisory Board of Evotec AG and the Board of Momentum Gruppen A/S.
About Uli Hacksell
Uli Hacksell, born in 1950, is a pharmacist, Doctor of Pharmaceutical Science and Associate Professor at Uppsala University. He is acting CEO and member of the Board of Medivir AB. In addition, Uli Hacksell holds a position as Chairman of the Board of Adhera Therapeutics Inc. and a member of the Board of Beactica AB, Cerecor Inc, InDex Pharmaceuticals AB, and Uppsala University.
About Active Biotech
Active Biotech AB is a biotechnology company with a focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA, immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects.
For more information: https://www.activebiotech.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.